Clinical Trial Update: Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 clinical trial evaluating the immunogenicity and safety of the EG-MCV4 meningococcal conjugate vaccine in healthy adults aged 19 to 55. The study is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Infections

Drugs mentioned

• EG-MCV4 (Meningococcal conjugate vaccine)

Snippet

Sponsor: EyeGene Inc. | Conditions: Meningococcal Infections | Phase 2, Phase 3 | Status: RECRUITING